Quick Answer
Intellia Therapeutics, Inc. reported Earnings Per Share Diluted of $3.81 (loss) per share for the year ending 2025.
- Intellia Therapeutics, Inc. showed an increase of +27.4% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $1.01 (loss) per share | Q3 2021: $0.97 (loss) per share | Q1 2022: $1.96 (loss) per share | Q2 2022: $1.33 (loss) per share | Q3 2022: $1.49 (loss) per share | Q1 2023: $1.17 (loss) per share | Q2 2023: $1.40 (loss) per share | Q3 2023: $1.38 (loss) per share | Q1 2024: $1.12 (loss) per share | Q2 2024: $1.52 (loss) per share | Q3 2024: $1.34 (loss) per share | Q1 2025: $1.10 (loss) per share | Q2 2025: $0.98 (loss) per share | Q3 2025: $0.92 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Intellia Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 58.8%.
- Historical annual values: Fiscal year 2025: $3.81 (loss) per share | Fiscal year 2024: $5.25 (loss) per share | Fiscal year 2023: $5.42 (loss) per share | Fiscal year 2022: $6.16 (loss) per share | Fiscal year 2021: $3.78 (loss) per share | Fiscal year 2020: $2.40 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: